Oral Bitter Agent Formulation for Asthma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for asthma often require inhalation of bitter agents, which can be difficult to administer and may not provide adequate control for many patients, leading to a need for non-inhaled, more effective formulations.

Innovation Solution

An oral pharmaceutical formulation combining bitter agents such as denatonium salts (e.g., denatonium benzoate or denatonium acetate) with formoterol, which is administered orally to treat asthma by relaxing airway smooth muscle cells without activating bitter taste receptors in the mouth.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bitter agents are administered by inhalation, then they can directly reach the airways and exert therapeutic effect, but patient compliance deteriorates due to the bitter taste activating mouth taste receptors

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent introduces an oral absorption intermediary system that allows bitter agents to bypass the oral cavity's taste receptors. By designing formulations that enable direct absorption through the oral mucosa or gastrointestinal tract, the bitter compounds reach systemic circulation without activating TAS2R taste receptors in the mouth, thus maintaining patient compliance while delivering therapeutic effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent transitions the administration route from the respiratory dimension (inhalation) to the gastrointestinal/oral mucosal dimension (oral administration). This dimensional shift allows the drug to bypass the taste sensing pathway while still achieving therapeutic delivery to the airways through systemic circulation

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

2Productivity

If currently available asthma agents are used, then treatment is provided for many patients, but at least one-half of all patients have inadequate control of the disease

Engineering Contradiction:

Improvedisease control coverageVSAvoiddisease control adequacy

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the pharmacological parameters by introducing a novel mechanism of action through bitter taste receptor agonists that relax airway smooth muscle. This new parameter (TAS2R receptor activation) complements existing GPCR-based treatments, providing enhanced efficacy for patients who respond inadequately to conventional therapies

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite therapeutic formulations combining bitter agents (such as denatonium benzoate) with conventional asthma medications like formoterol. This composite approach leverages multiple mechanisms of action - TAS2R receptor agonism for smooth muscle relaxation and beta-2 agonism for bronchodilation - to achieve superior disease control in patients with inadequate response to single-mechanism therapies

Inventive Principle:

Principle #40Composite materials

3Reliability

If higher doses of formoterol are used to improve asthma control, then symptom relief is enhanced, but the need for combination formulations arises to achieve synergistic effects with lower doses

Engineering Contradiction:

Improveasthma controlVSAvoidformoterol dosage

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent merges two distinct pharmacological mechanisms into a single formulation: TAS2R receptor agonism (bitter agents causing smooth muscle relaxation) and beta-2 adrenergic agonism (formoterol causing bronchodilation). This combination produces synergistic bronchodilator effects, allowing achievement of equivalent or superior asthma control with lower formoterol doses compared to monotherapy

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The oral formulation demonstrates a synergistic effect with formoterol, providing effective bronchodilation and improving asthma control with lower doses of formoterol, thus overcoming the limitations of inhalation-based treatments.

Implementation Method 1

bitter agents such as denatonium salts (e.g., denatonium benzoate or denatonium acetate)... agonists of TAS2R receptors

Methodology Applied

Scientific EffectTAS2R receptor activation:

Implementation Method 2

formoterol... long-acting bronchodilator... works in the airways by relaxing muscles and opening air passages

Methodology Applied

Scientific EffectBeta-2 adrenergic receptor agonism:

Implementation Method 3

oral pharmaceutical formulation... administered orally

Methodology Applied

Scientific EffectOral absorption: Absorption (physical)

Data Source

PatentUS12201593B2Oral pharmaceutical formulations of bitter compounds for asthma

Publication Date: 2025.01.21 AARDVARK THERAPEUTICS INC

AI summary

There is disclosed an oral pharmaceutical formulation of bitter compounds that are agonists of TAS2R receptors for the treatment of asthma. More specifically, the present disclosure provides an asthma oral formulation comprising a bitter agent selected from the group consisting of denatonium benzoate (DB), denatonium chloride (DC), denatonium saccharide (DS), denatonium acetate (DA), and combinations thereof and formoterol.